LEO Pharma

LEO Pharma A/S og FibroTx LLC indgår samarbejde om udvikling af ikke-invasiv hudsampling

Del

Ballerup, den 13. juni, 2018 – LEO Pharma og FibroTx har indgået samarbejde om udviklingen af ny teknologi til ikke-invasiv hudsampling. FibroTx er et biotek-selskab med base i Estland, som udvikler innovative værktøjer til målrettet dermatologisk behandling.

Samarbejdet er det første skridt på vejen mod at kunne måle biomarkører fra hudoverfladen hos patienter med atopisk dermatitis ved brug af en ikke-invasiv hudsampling-metode, som FibroTx har udviklet. Metoden kan anvendes til at bestemme omfang af sygdommen samt til at overvåge effekten af behandling. Det er endvidere også muligt, at metoden vil kunne anvendes til at vurdere fremtidig effekt af behandling.

Samarbejdet mellem LEO Pharma og FibroTx om udviklingen af målrettede medicinske værktøjer, der medfører mindst muligt ubehag for patienterne, styrker begge virksomheders indsats for at forbedre livet for mennesker, som er ramt af atopisk dermatitis.

”Vi er glade for at indgå samarbejde med FibroTx om deres nye teknologi, som vil hjælpe os med at måle den terapeutiske respons på vores behandling. Det er især vigtigt at kunne tilbyde hudsampling med minimalt ubehag til patienter, hvis hud allerede er påvirket,” siger Per Sprøgel, Vice President, Medical Science and Safety hos LEO Pharma.

”Vi ser aftalen med LEO Pharma som en vigtig anerkendelse af potentialet inden for vores non-invasive diagnostiske platform. Vores samarbejde vil i den grad styrke vores arbejde med udviklingen af praktiske hjemme-tests, som kan forbedre den måde vi behandler patienter med atopisk dermatitis på i dag,” siger Pieter Spee, Chief Technology Officer, FibroTx LLC.

Kort om FibroTex teknologi: FibroTx TAP er en non-invasiv ELISA-baseret (Enzyme Linked Immunosorbent Assay) platformteknologi, hvor proteiner opfanges direkte fra hudoverfladen ved hjælp af specifikke antistoffer. TAP er både mere bekvem, sensitiv og reproducerbar sammenlignet med konventionelle proteinbaserede teknologier. FibroTx SELF er en non-invasiv testplatform baseret på lateral-flow, hvor vaskeprøver opsamlet fra huden analyseres i en hurtig test, der kan aflæses ved hjælp af mobiltelefon eller lateral flowtest-læser afhængig af anvendelsen.

Om FibroTx

FibroTx LLC (Talin, Estland) er et privatejet selskab, der fokuserer på udvikling af non-invasive diagnostiske tests til anvendelse indenfor dermatologi og hudpleje. FibroTx har udviklet to diagnostiske platforme, TAP og SELF, som mulliggør måling af et panel af biomarkører direkte fra hudoverfladen. FibroTx leder programmer i klinisk dermatologi, der er rettet imod udvikling af point-of-care instrumenter baseret på lateral flow teknologi, der kan monitorere og vejlede hjemmebehandling af psoriasis- og atopisk dermatit-patienter.

Kontakter

Trine Juul Wengel, Corporate Communication Manager
LEO Pharma A/S
tewdk@leo-pharma.com
Tlf.: 20732037

Information om LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

Om LEO Pharma

LEO Pharma hjælper mennesker til at få en sund hud. Ved at tilbyde løsninger til patienter i mere end 130 lande på verdensplan hjælper LEO Pharma mennesker til at håndtere deres hudlidelser. Grundlagt i 1908 og ejet af LEO Fondet har lægemiddelvirksomheden dedikeret årtiers forskning og udvikling til at levere produkter og løsninger til mennesker med hudlidelser. LEO Pharma har hovedkvarter i Danmark og har på ca. 5.200 ansatte over hele verden.

Website: www.leo-pharma.com

LinkedIn: www.linkedin.com/company/leo-pharma
YouTube: www.youtube.com/leopharmaglobal

 

Følg pressemeddelelser fra LEO Pharma

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra LEO Pharma

LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate15.4.2020 07:45:16 CESTPress release

BALLERUP, Denmark, April 15, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, TPEx: 4743) and Microbio Shanghai (China) covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.

LEO Pharma Group completes divestment of Emollients and Proctology Portfolio to Karo Pharma2.3.2020 12:05:26 CETPress release

Ballerup, DENMARK, March 2, 2020 – LEO Pharma today announced that the divestment of its emollients and proctology portfolio to Karo Pharma for 90 MEUR has been completed. The initial agreement with Karo Pharma was announced on December 23, 2019 and approved by relevant competition authorities on February 20, 2020. This divestment marks an important step for LEO Pharma towards strategically aligning its portfolio and increasing focus on innovation and dermatology. The divested products include four anti-hemorrhoid products (Sheriproct®, Doloproct®, Neriproct® and Ultraproct®) and six dermatology products, mainly over-the-counter products (Ultrabas®, Ultralip®, Ultraphil®, Ultrasicc®, Neribas® and Ultralan®).

With topline growth of 7% in 2019, margin improvements and pipeline success, LEO Pharma paves the way for an ambitious future27.2.2020 21:00:00 CETPress release

LEO Pharma helped 92 million patients and reached revenue of DKK 10,805 million in 2019 - 2019 revenue up by 4% to DKK 10,805 million – with a strong fourth quarter demonstrating further momentum. This was driven by strong performances of Enstilar®, Kyntheum® and the prescription portfolio acquired from Bayer. - Underlying revenue grew by 7%. This excludes currency effects, divestments of non-core business to Karo Pharma and other one-time effects. - Revenue in region Europe+ grew 5% to DKK 6,840 million, due to Enstilar®, Kyntheum® and the acquired Bayer portfolio. - Sales in region International grew 12% to DKK 3,117 million, due to the acquired Bayer portfolio. - US sales declined 22% to DKK 848 million, due to generic competition and price pressure. We continue to see the US as a key growth driver in the future and are stepping up the launch preparations for tralokinumab accordingly. Established business remains the backbone with continued growth and improved profitability - Toplin

LEO Pharma Signs Agreement to Divest Emollients and Proctology Portfolio to Karo Pharma23.12.2019 12:10:00 CETPress release

Ballerup, DENMARK, December 23, 2019 – Today, LEO Pharma announced the sale of 10 products to Karo Pharma AB for 90 MEUR. The divested portfolio isnon-core to LEO Pharma’s business, and was part of the portfolio acquired from Bayer in July 2019. “This divestment is an important step for LEO Pharma towards strategically aligning our portfolio and increasing focus on innovation and dermatology. This well-established portfolio will be better served by Karo Pharma and its team,” said Anders Kronborg, Chief Financial Officer, LEO Pharma. The product portfolio includes four anti-haemorrhoid products (Sheriproct®, Doloproct®, Neriproct® and Ultraproct®) and six dermatology, mainly over-the-counter products (Ultrabas®, Ultralip®, Ultraphil®, Ultrasicc®, Neribas® and Ultralan®). Karo Pharma is a fast-growing specialty pharma company that develops and markets products to physicians, pharmacies and directly to healthcare providers. The company is listed on the Swedish stock exchange, Nasdaq Stock

LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD11.12.2019 08:05:00 CETPress release

BALLERUP, Denmark, December 11, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced that tralokinumab – an investigational, fully human monoclonal antibody that specifically neutralizes the interleukin-13 (IL-13) cytokine – met all primary and secondary endpoints in its three pivotal Phase 3 studies (ECZTRA 1-3) for the treatment of moderate-to-severe atopic dermatitis (AD) in adults. During the studies, the overall adverse event rate was comparable between tralokinumab and placebo. IL-13 is a key driver of the type 2 inflammation that plays a major role in AD,(1) which is the most common inflammatory skin disease in the developed world,(2) affecting up to five percent of adults across the United States, Canada, Europe and Japan.(3) AD can have a significant, negative impact on patients’ well-being, primarily due to distressing itch, sleep deprivation and social stigmatization due to visible lesions.(4) “In its moderate-to-severe form, AD can cause unbearable

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum